Enzymatica AB (publ) (ENZY.ST)
SEK 1.68
(-1.18%)
SEK 1.68
(-1.18%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 50.9 Million SEK | 4.0% |
| 2022 | 48.94 Million SEK | -14.49% |
| 2021 | 57.24 Million SEK | -48.54% |
| 2020 | 111.24 Million SEK | 81.46% |
| 2019 | 61.3 Million SEK | 16.64% |
| 2018 | 52.56 Million SEK | -11.58% |
| 2017 | 59.44 Million SEK | 62.95% |
| 2016 | 36.48 Million SEK | 30.7% |
| 2015 | 27.91 Million SEK | 46.42% |
| 2014 | 19.06 Million SEK | 81.74% |
| 2013 | 10.48 Million SEK | 1071.96% |
| 2012 | 895 Thousand SEK | 53.78% |
| 2011 | 582 Thousand SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 9.4 Million SEK | -40.63% |
| 2024 Q2 | 6.42 Million SEK | -31.62% |
| 2023 Q3 | 13.26 Million SEK | 51.39% |
| 2023 Q4 | 15.83 Million SEK | 19.34% |
| 2023 FY | 50.9 Million SEK | 4.0% |
| 2023 Q1 | 13.03 Million SEK | -21.62% |
| 2023 Q2 | 8.76 Million SEK | -32.78% |
| 2022 Q3 | 18.52 Million SEK | 92.54% |
| 2022 Q4 | 16.63 Million SEK | -10.22% |
| 2022 FY | 48.94 Million SEK | -14.49% |
| 2022 Q1 | 4.16 Million SEK | -77.79% |
| 2022 Q2 | 9.62 Million SEK | 131.21% |
| 2021 Q2 | 6.1 Million SEK | -64.02% |
| 2021 Q4 | 18.74 Million SEK | 21.59% |
| 2021 FY | 57.24 Million SEK | -48.54% |
| 2021 Q1 | 16.97 Million SEK | -59.82% |
| 2021 Q3 | 15.41 Million SEK | 152.32% |
| 2020 Q1 | 26.78 Million SEK | 20.92% |
| 2020 Q4 | 42.26 Million SEK | 49.52% |
| 2020 Q3 | 28.26 Million SEK | 102.86% |
| 2020 Q2 | 13.93 Million SEK | -47.98% |
| 2020 FY | 111.24 Million SEK | 81.46% |
| 2019 FY | 61.3 Million SEK | 16.64% |
| 2019 Q4 | 22.15 Million SEK | 13.61% |
| 2019 Q2 | 6.36 Million SEK | -52.1% |
| 2019 Q1 | 13.28 Million SEK | -29.85% |
| 2019 Q3 | 19.49 Million SEK | 206.35% |
| 2018 Q4 | 18.94 Million SEK | 43.17% |
| 2018 FY | 52.56 Million SEK | -11.58% |
| 2018 Q3 | 13.23 Million SEK | 149.99% |
| 2018 Q2 | 5.29 Million SEK | -64.93% |
| 2018 Q1 | 15.09 Million SEK | -21.07% |
| 2017 FY | 59.44 Million SEK | 62.95% |
| 2017 Q4 | 19.11 Million SEK | -22.95% |
| 2017 Q1 | 9.61 Million SEK | -11.33% |
| 2017 Q2 | 5.9 Million SEK | -38.56% |
| 2017 Q3 | 24.81 Million SEK | 320.27% |
| 2016 Q2 | 4.89 Million SEK | -41.84% |
| 2016 Q3 | 12.34 Million SEK | 152.25% |
| 2016 Q4 | 10.83 Million SEK | -12.17% |
| 2016 Q1 | 8.41 Million SEK | -23.89% |
| 2016 FY | 36.48 Million SEK | 30.7% |
| 2015 Q3 | 6.81 Million SEK | 120.77% |
| 2015 FY | 27.91 Million SEK | 46.42% |
| 2015 Q4 | 11.05 Million SEK | 62.22% |
| 2015 Q1 | 6.96 Million SEK | -19.77% |
| 2015 Q2 | 3.08 Million SEK | -55.67% |
| 2014 Q4 | 8.67 Million SEK | 31.49% |
| 2014 Q1 | 2.52 Million SEK | -57.87% |
| 2014 Q3 | 6.59 Million SEK | 420.76% |
| 2014 Q2 | 1.26 Million SEK | -49.76% |
| 2014 FY | 19.06 Million SEK | 81.74% |
| 2013 Q2 | 498 Thousand SEK | -63.33% |
| 2013 Q4 | 5.98 Million SEK | 126.14% |
| 2013 FY | 10.48 Million SEK | 1071.96% |
| 2013 Q3 | 2.64 Million SEK | 431.53% |
| 2013 Q1 | 1.35 Million SEK | 274.08% |
| 2012 FY | 895 Thousand SEK | 53.78% |
| 2012 Q3 | 357.52 Thousand SEK | 1220.19% |
| 2012 Q2 | 27.08 Thousand SEK | -81.49% |
| 2012 Q1 | 146.27 Thousand SEK | 0.0% |
| 2012 Q4 | 363.02 Thousand SEK | 1.54% |
| 2011 Q2 | 6952.00 SEK | 0.0% |
| 2011 FY | 582 Thousand SEK | 0.0% |
| 2011 Q3 | 394.35 Thousand SEK | 5572.54% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 Q3 | 39.8 Thousand SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 1.29 Billion SEK | 96.074% |
| Enorama Pharma AB (publ) | 1.35 Million SEK | -3648.454% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | - SEK | -Infinity% |
| Nanexa AB (publ) | 29.32 Million SEK | -73.574% |
| Newbury Pharmaceuticals AB (publ) | 36.82 Million SEK | -38.217% |
| ODI Pharma AB | 22.44 Million SEK | -126.773% |
| Orexo AB (publ) | 638.8 Million SEK | 92.031% |
| Probi AB (publ) | 627.68 Million SEK | 91.89% |
| Swedencare AB (publ) | 2.32 Billion SEK | 97.81% |
| Swedish Orphan Biovitrum AB (publ) | 22.12 Billion SEK | 99.77% |
| Toleranzia AB | 50.92 Million SEK | 0.031% |
| Vivesto AB | 1.01 Million SEK | -4915.172% |